JMP Securities has initiated coverage on Enovis Corporation (ENOV), a medical technology company specializing in orthopedics, with a ‘Market Outperform’ rating and a price target of $62. The analyst believes Enovis is undervalued, citing the successful integration of the LimaCorporate acquisition and the potential for significant revenue and earnings growth.